Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Relmada Therapeutics, Inc. (RLMD : NSDQ)

• Company Description    Relmada Therapeutics Inc. is a clinical stage, public specialty pharmaceutical company. The Company is developing LevoCap ER, an abuse resistant, once-a-day sustained release dosage form of the opioid analgesic levorphanol; d-methadone, the NDMA receptor antagonist for neurophatic pain; BuTab ER, an oral dosage form of the opioid analgesic buprenorphine and MepiGel, a FDA Orphan Drug designated topical formulation of the local anesthetic mepivacaine. Relmada Therapeutics Inc. is based in New York. Number of Employees: 17

• Price / Volume Information    Yesterday's Closing Price: $1.59 Daily Weekly Monthly 20 Day Moving Average: 1,626,126 shares Shares Outstanding: 33.19 (millions) Market Capitalization: $52.78 (millions) Beta: 0.74 52 Week High: $3.98 52 Week Low: $0.24 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 161.86% 157.25% 12 Week 127.18% 106.36% Year To Date 205.77% 160.99%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 2222 PONCE DE LEON BLVD. 3RD FLOOR - CORAL GABLES,FL 33134 USA ph: 786-629-1376 fax: - britchie@lifesciadvisors.com http://www.relmada.com

• General Corporate Information    Officers Sergio Traversa - Chief Executive Officer; and Director Charles J. Casamento - Chairman of the Board Maged Shenouda - Chief Financial Officer Paul Kelly - Director John Glasspool - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-DRUGS Sector: Medical CUSIP: 75955J402 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/25 Next Expected EPS Date: 11/06/25 Share - Related Items Shares Outstanding: 33.19 Most Recent Split Date: 9.00 (0.25:1) Beta: 0.74 Market Capitalization: $52.78 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.04 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/06/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 3.31 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 49.15% vs. Previous Quarter: 48.28% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 06/30/25 - -223.17 03/31/25 - -181.26 12/31/24 - -147.64 ROA 06/30/25 - -180.41 03/31/25 - -151.23 12/31/24 - -124.49 Current Ratio 06/30/25 - 4.11 03/31/25 - 5.29 12/31/24 - 4.45 Quick Ratio 06/30/25 - 4.11 03/31/25 - 5.29 12/31/24 - 4.45 Operating Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Net Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Pre-Tax Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Book Value 06/30/25 - 0.48 03/31/25 - 0.68 12/31/24 - 1.18 Inventory Turnover 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Equity 06/30/25 - 0.00 03/31/25 - 0.00 12/31/24 - 0.00 Debt-to-Capital 06/30/25 - 0.00 03/31/25 - 0.00 12/31/24 - 0.00

Powered by Zacks Investment Research ©